BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3010055)

  • 1. Ovarian function during oestrogen-progestin replacement treatment in pre-menopausal women.
    Ylöstalo P; Vartiainen E; Stenman UH; Widholm O
    Maturitas; 1986 Mar; 8(1):19-27. PubMed ID: 3010055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of levonorgestrel-releasing intrauterine device on hormonal profile and menstrual pattern after long-term use.
    Xiao B; Zeng T; Wu S; Sun H; Xiao N
    Contraception; 1995 Jun; 51(6):359-65. PubMed ID: 7554977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cycle and hormone changes during perimenopause: the key role of ovarian function.
    Burger HG; Hale GE; Dennerstein L; Robertson DM
    Menopause; 2008; 15(4 Pt 1):603-12. PubMed ID: 18574431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasonographic and endocrine evaluation of ovarian function among Norplant implants users with regular menses.
    Alvarez F; Brache V; Faundes A; Tejada AS; Thevenin F
    Contraception; 1996 Nov; 54(5):275-9. PubMed ID: 8934060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of a sequential regimen of mifepristone-medroxyprogesterone acetate on ovarian function, endometrial development and hormonal parameters.
    Croxatto HB; Massai MR; Salvatierra AM; Fuentealba B; Croxatto HD; Lähteenmäki P
    Contraception; 1996 Aug; 54(2):79-86. PubMed ID: 8842583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A regimen of oral contraceptives restricted to the periovulatory period may permit folliculogenesis but inhibit ovulation.
    Letterie GS
    Contraception; 1998 Jan; 57(1):39-44. PubMed ID: 9554249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel.
    Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U
    Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of FSH, LH, estradiol-17 beta and progesterone following the administration of a combined oral contraceptive containing 20 micrograms ethinylestradiol.
    Carlström K; Lunell NO; Zador G
    Gynecol Obstet Invest; 1978; 9(6):304-11. PubMed ID: 754992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women.
    Hirvonen E; Stenman UH; Mälkönen M; Rasi V; Vartiainen E; Ylöstalo P
    Maturitas; 1988 Oct; 10(3):201-13. PubMed ID: 2972897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
    Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of ovulation by progestin analogs (agonists vs antagonists): preliminary evidence for different sites and mechanisms of actions.
    Heikinheimo O; Gordon K; Williams RF; Hodgen GD
    Contraception; 1996 Jan; 53(1):55-64. PubMed ID: 8631191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of follicle-stimulating hormone, luteinizing hormone, oestradiol-17 beta and progesterone, and follicular growth in the pseudopregnant rat.
    Welschen R; Osman P; Dullaart J; de Greef WJ; Uilenbroek JT; de Jong FH
    J Endocrinol; 1975 Jan; 64(1):37-47. PubMed ID: 1167896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis.
    Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT
    Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants.
    Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F
    Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follicle growth and endocrine dynamics in women with spontaneous luteinized unruptured follicles versus ovulation.
    Bashir ST; Baerwald AR; Gastal MO; Pierson RA; Gastal EL
    Hum Reprod; 2018 Jun; 33(6):1130-1140. PubMed ID: 29659847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian activity suppression by two different low-dose triphasic oral contraceptives.
    van der Does J; Exalto N; Dieben T; Bennink HC
    Contraception; 1995 Dec; 52(6):357-61. PubMed ID: 8749599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation between plasma hormone profiles, symptoms, and response to oestrogen treatment in women approaching the menopause.
    Chakravarti S; Collins WP; Thom MH; Studd JW
    Br Med J; 1979 Apr; 1(6169):983-5. PubMed ID: 219937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.